In Silico and In Vitro Inhibition of SARS-CoV-2 PLpro with Gramicidin D

Int J Mol Sci. 2023 Jan 19;24(3):1955. doi: 10.3390/ijms24031955.

Abstract

Finding an effective drug to prevent or treat COVID-19 is of utmost importance in tcurrent pandemic. Since developing a new treatment takes a significant amount of time, drug repurposing can be an effective option for achieving a rapid response. This study used a combined in silico virtual screening protocol for candidate SARS-CoV-2 PLpro inhibitors. The Drugbank database was searched first, using the Informational Spectrum Method for Small Molecules, followed by molecular docking. Gramicidin D was selected as a peptide drug, showing the best in silico interaction profile with PLpro. After the expression and purification of PLpro, gramicidin D was screened for protease inhibition in vitro and was found to be active against PLpro. The current study's findings are significant because it is critical to identify COVID-19 therapies that are efficient, affordable, and have a favorable safety profile.

Keywords: COVID-19; PLpro; PLpro candidate inhibitor; anti SARS-CoV-2; gramicidin D.

MeSH terms

  • Antiviral Agents / pharmacology
  • COVID-19*
  • Databases, Factual
  • Gramicidin
  • Humans
  • Molecular Docking Simulation
  • Protease Inhibitors / pharmacology
  • SARS-CoV-2*

Substances

  • Gramicidin
  • Protease Inhibitors
  • Antiviral Agents